<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo>-trans-<z:chebi fb="2" ids="26536">retinoic acid</z:chebi> (ATRA) alone or in combination with cytokines and vitamins has been shown to stimulate erythropoiesis in low-risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We performed a phase II study on 29 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and isolated del(5q) including bands q31-q33 to determine the efficacy and safety of ATRA in combination with <z:chebi fb="1" ids="27013">tocopherol</z:chebi>-alpha </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients had low/intermediate-1 risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> according to the international prognostic scoring system </plain></SENT>
<SENT sid="3" pm="."><plain>They received 45 mg/m(2) ATRA on days 1 to 90, and 90 mg/m(2) on days 91 to 180 </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="1" ids="27013">Tocopherol</z:chebi> dosage was 600 IU three times daily </plain></SENT>
<SENT sid="5" pm="."><plain>Twenty-four patients completed dose level I, and 12 patients dose level II </plain></SENT>
<SENT sid="6" pm="."><plain>Eighty-six percent of patients experienced side effects </plain></SENT>
<SENT sid="7" pm="."><plain>Thirty discontinued the drug treatment due to such events as skin reactions, <z:hpo ids='HP_0100825'>cheilitis</z:hpo>, <z:hpo ids='HP_0000509'>conjunctivitis</z:hpo>, <z:hpo ids='HP_0002829'>joint pain</z:hpo>, <z:chebi fb="0" ids="16737">creatinine</z:chebi> increase, or <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> symptoms </plain></SENT>
<SENT sid="8" pm="."><plain>One patient (3%) achieved a major erythroid response resulting in transfusion independence throughout the study </plain></SENT>
<SENT sid="9" pm="."><plain>Four patients (14%) achieved a minor erythroid response with &gt;50% reduction of transfusion needs </plain></SENT>
<SENT sid="10" pm="."><plain>None of the participants had a cytogenetic response </plain></SENT>
<SENT sid="11" pm="."><plain>There was no significant improvement in quality of life among responding patients as measured by the European Organization for the Research and Treatment of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> (EORTC) quality of life questionnaire </plain></SENT>
<SENT sid="12" pm="."><plain>Based on these results, the combination of ATRA and <z:chebi fb="1" ids="27013">tocopherol</z:chebi>-alpha is not recommended for the treatment of del(5q) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>